Physician profile
Samuel E Scolaro
NPI 1174590772
$3,480.24
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,716 · 2020: $764.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $534.90 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $466.83 | 2019-2020 | |
| Amarin Pharma, INC. | $430.21 | 2019-2020 | |
| Amgen INC. | $291.77 | 2019-2020 | |
| Novo Nordisk INC | $224.74 | 2019 | |
| Lilly USA, LLC | $216.46 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $211.11 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $172.82 | 2019 | |
| Allergan, INC. | $166.86 | 2019-2020 | |
| Pfizer INC. | $130.93 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $84.06 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $80.31 | 2019-2020 | |
| Radius Health, INC. | $73.59 | 2019-2020 | |
| Abbvie INC. | $70.73 | 2019 | |
| Horizon Therapeutics Plc | $63.87 | 2019-2020 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $48.02 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $41.37 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $39.67 | 2019 | |
| Glaxosmithkline, LLC. | $19.26 | 2020 | |
| Arbor Pharmaceuticals, INC. | $16.40 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $12.05 | 2019 | |
| Smith+Nephew, INC. | $11.53 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Scolaro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.